Reversible Cerebral Vasoconstriction Syndrome With Concomitant Transient Global Amnesia

• Sponsor: University Hospital, Montpellier (Other)
• Overall Status: Completed
• CT.gov ID: NCT03739008
• Collaborator: (none)
• Enrollment: 3
• Location: 1
• Actual Duration (Months): 82.2
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by severe, unusual headaches associated with multifocal segmental vasoconstriction of the intracerebral arteries. In addition to headache, focal neurological deficit and/or seizures are quite frequently described, but anterograde amnesia seems to but extremely rare. Indeed, to date, only one case of RCVS associated with transient global amnesia (TGA) has been published. In case of an atypical presentation of TG, associated with brutal headaches, it is important not to ignore an assocation with RCVS because management, treatment, evolution and prognosis are different. Indeed, TGA is a monophasic phenomenon of less than 24 hours duration, without associated complications, which does not require any particular treatment. On the other hand, RCVS, although most often of excellent prognosis, can have severe complications such as intracerebral hemorrhage, subarachnoid hemorrhage, posterior reversible encephalopathy syndrome and cerebral infarction. In order to limit headaches and potential complications, RCVS require special management, including symptomatic treatments for headaches, complete rest, removal of precipitin factors and introduction of calcium channel blockers for a few weeks.

This study aim to described three cases of patient who presented with concomitant TGA and RCVS, and to discuss pathogenic mechanism which may be similar in both these pathologies.

Condition or Disease	Intervention/Treatment	Phase
Transient Global Amnesia; Reversible Vasoconstriction Syndrome

Study Design

• Study Type: Observational
• Actual Enrollment: 3 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: Reversible Cerebral Vasoconstriction Syndrome With Concomitant Transient Global Amnesia : a Serie of 3 Cases Report
• Actual Study Start Date: Jan 1, 2012
• Actual Primary Completion Date: Nov 8, 2018
• Actual Study Completion Date: Nov 8, 2018

Outcome Measures

Primary Outcome Measures

1. Occurrence of concomitant TGA and proven RCVS [1 day]

   Occurrence of concomitant transient global amnesia (TGA) and proven Reversible cerebral vasoconstriction syndrome (RCVS)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients with a proven or probable RCVS concomitant with certain transient global amnesia

Exclusion Criteria:

• Not proven transient global amnesia, not proven or possible RCVS

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Uhmontpellier	Montpellier		France	34295

Sponsors and Collaborators

• University Hospital, Montpellier

Investigators

• Principal Investigator: Nicolas Gaillard, MD, University Hospital, Montpellier

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University Hospital, Montpellier
• ClinicalTrials.gov Identifier: NCT03739008
• Other Study ID Numbers: RECHMPL18_0423
• First Posted: Nov 13, 2018
• Last Update Posted: Aug 12, 2019
• Last Verified: Nov 1, 2018

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by University Hospital, Montpellier: Thunderclap headache
• Additional relevant MeSH terms: Amnesia; Amnesia, Transient Global; Syndrome

Study Results

No Results Posted as of Aug 12, 2019